These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15818764)

  • 21. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    Tavintharan S; Lim SC; Sum CF
    Singapore Med J; 2005 Oct; 46(10):519-28. PubMed ID: 16172771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
    Canner PL; Furberg CD; McGovern ME
    Am J Cardiol; 2006 Feb; 97(4):477-9. PubMed ID: 16461040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Don't overlook niacin for treating cholesterol problems. If you can conquer or cope with the "niacin flush," this B vitamin can do wonders for cholesterol.
    Harv Heart Lett; 2004 Apr; 14(8):4-5. PubMed ID: 15100082
    [No Abstract]   [Full Text] [Related]  

  • 25. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV
    Int J Clin Pract; 2007 Nov; 61(11):1942-8. PubMed ID: 17935553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-density lipoprotein cholesterol: current perspective for clinicians.
    Whayne TF
    Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDL: who needs it?
    Wierzbicki AS
    Int J Clin Pract; 2011 Nov; 65(11):1111-3. PubMed ID: 21995687
    [No Abstract]   [Full Text] [Related]  

  • 32. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM; Bamba R
    Am J Cardiol; 2008 Apr; 101(8A):44B-47B. PubMed ID: 18375241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP
    Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
    Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
    Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2005 Jul; 20(4):365-8. PubMed ID: 16124142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.